Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

Justice Dept. And S.E.C. Investigating Merck Drug

Article Abstract:

Merck & Company Inc., the makers of the recently withdrawn COX-2 inhibitor Vioxx, is under investigation. Both the Securities and Exchange Commission and the Justice Department are looking into when the company became aware of the risks of Vioxx, and the subsequent disclosure of that information.

Author: Pollack, Andrew
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
Legal issues & crime, Product information, Company legal issue, Investigations, Labeling, United States. Securities and Exchange Commission, Vioxx (Medication), Merck & Company Inc., Bextra (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Ban or No Ban, Celebrex Sales Are Expected To Dwindle

Article Abstract:

Shares of pharmaceutical company, Pfizer Inc., have fallen over 15 percent in the last week, after research showed that Celebrex, one of its major products increased the risk of heart attack. Analysts expect that Pfizer's sales will drop from $51.1 billion in 2004 to $46.5 billion in 2007.

Author: Berenson, Alex
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
Forecasts, trends, outlooks, Dosage and administration, Celebrex (Medication), Company business forecast/projection, Company forecasts

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Heart Ailment Warning on Cancer Drug

Article Abstract:

The Food and Drug Administration and Genentech Inc. are issuing a warning about potentially lethal side effects of the colorectal cancer drug Avastin.

Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
Brief Article, Risk factors, Powers and duties, Genentech Inc., United States. Food and Drug Administration, DNA, Avastin (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Product defects and recalls, Pharmaceutical industry, Complications and side effects, Pfizer Inc., COX-2 inhibitors, PFE, Securities, Company securities
Similar abstracts:
  • Abstracts: Genentech In Competition With Itself On Eye Drug. In Trial, Drug Aids Vision Of Elderly
  • Abstracts: Producer Price Surge Fuels Inflation Fears. Price Report Eases Fears On Inflation. Market Slide Leaves Dow Below 10,000
  • Abstracts: Panel to Review Drug for Low Female Sex Drive. A New Trial of Celebrex, and Questions on Its Timing
  • Abstracts: Plan to Seize Yukos Unit Is Ruled Illegal by Court. Bank Asks Court to Dismiss Yukos Bankruptcy. Yukos Sale Deepens Investor Doubts
  • Abstracts: Britain Grants License to Make Human Embryos for Stem Cells. Oil Prospecting Under Kremlin Watch
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.